• CRISPR-Cas RNP complexes provide a non-viral, efficient delivery method for gene editing in hematopoietic stem cells, offering rapid activity and reduced off-target effects.
• Novel delivery techniques including microfluidic-based methods, filtroporation, nanoparticles, and cell-penetrating peptides are advancing the clinical application of CRISPR-Cas RNP for hematologic disorder therapies.
• The review highlights the potential of RNP delivery to overcome hurdles in HSC gene editing, paving the way for safer and more effective genetic treatments.
• Optimizing delivery strategies is crucial for translating CRISPR-Cas RNP technology into clinical practice for hematologic diseases.